Regeneron Pharmaceuticals (REGN) stock price, revenue, and financials

Regeneron Pharmaceuticals market cap is $69 b, and annual revenue was $7.86 b in FY 2019

$69 B

REGN Mkt cap, 29-May-2020

$1.8 B

Regeneron Pharmaceuticals Revenue Q1, 2020
Regeneron Pharmaceuticals Net income (Q1, 2020)624.6 M
Regeneron Pharmaceuticals EBIT (Q1, 2020)700.1 M
Regeneron Pharmaceuticals Cash, 31-Mar-20202.2 B
Regeneron Pharmaceuticals EV67.5 B

Regeneron Pharmaceuticals Revenue

Regeneron Pharmaceuticals revenue was $7.86 b in FY, 2019 which is a 17.2% year over year increase from the previous period.

Embed Graph

Regeneron Pharmaceuticals Revenue Breakdown

Embed Graph

Regeneron Pharmaceuticals revenue breakdown by business segment: 33.3% from Sanofi and Bayer Collaboration, 61.5% from Product Sales and 5.3% from Other

Regeneron Pharmaceuticals Income Statement

Regeneron Pharmaceuticals Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

535.2m812.7m1.5b1.6b

Accounts Receivable

1.6b2.0b2.2b2.7b

Prepaid Expenses

130.5m225.0m243.3m387.1m

Inventories

399.4m726.1m1.2b1.4b

Current Assets

3.2b4.3b6.4b7.7b

PP&E

2.1b2.4b2.6b2.9b

Total Assets

7.0b8.8b11.7b14.8b

Accounts Payable

879.1m815.1m218.2m418.1m

Short-term debt

127.3m

Current Liabilities

1.2b1.1b1.4b2.1b

Long-term debt

351.6m703.5m708.5m713.9m

Total Debt

478.8m703.5m708.5m713.9m

Total Liabilities

2.5b2.6b3.0b3.7b

Common Stock

110.0k112.0k100.0k100.0k

Additional Paid-in Capital

3.0b3.5b3.9b4.4b

Retained Earnings

1.7b2.9b5.3b7.4b

Total Equity

4.4b6.1b8.8b11.1b

Debt to Equity Ratio

0.1 x0.1 x0.1 x0.1 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0 x

Financial Leverage

1.6 x1.4 x1.3 x1.3 x

Regeneron Pharmaceuticals Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

895.5m1.2b2.4b2.1b

Depreciation and Amortization

104.7m145.5m148.2m210.3m

Accounts Receivable

(143.8m)(362.7m)(268.9m)(473.1m)

Inventories

(149.8m)(314.2m)(387.9m)(335.5m)

Accounts Payable

254.0m(23.2m)210.0m444.5m

Cash From Operating Activities

1.5b1.3b2.2b2.4b

Capital Expenditures

(511.9m)(272.6m)(383.1m)(429.6m)

Cash From Investing Activities

(1.0b)(1.0b)(1.5b)(2.0b)

Long-term Borrowings

40.6m(19.9m)

Cash From Financing Activities

(700.4m)(24.4m)(77.1m)(252.1m)

Net Change in Cash

(273.9m)277.5m655.0m150.1m

Interest Paid

5.5m18.7m22.3m25.0m

Income Taxes Paid

481.4m754.8m205.6m342.3m

Free Cash Flow

961.5m1.0b1.8b2.0b

Regeneron Pharmaceuticals Ratios

USDY, 2020

EV/EBIT

96.4 x

Financial Leverage

1 x

Regeneron Pharmaceuticals Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Cell Culture Capacity, liters

97 k101 k100 k230 k

Facility Space Leased, square feet

1.18 m1.47 m1.47 m1.47 m

Facility Space Owned, square feet

1.56 m1.61 m1.61 m1.35 m

Patents (EU)

3 7 11 11

Patents (US)

6 17 18 21

Product Candidates

16 15 21 22

Products

5 6 7 7

Trademarks

8 9 12 13

Regeneron Pharmaceuticals Employee Rating

3.9702 votes
Culture & Values
3.9
Work/Life Balance
3.5
Senior Management
3.4
Salary & Benefits
4.1
Career Opportunities
3.7
Source